Dr. Joshua Zeidner is an Associate Professor of Medicine at the University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, where he is the Section Chief of Leukemia Research, Associate Chief of Research within the Division of Hematology, and the inaugural Director of Clinical Cancer Research, Commercial Integration, at Lineberger Comprehensive Cancer Center. Dr. Zeidner earned his medical degree from New York Medical College and then underwent training in internal medicine and Oncology at Johns Hopkins. Dr. Zeidner’s research focuses on drug development, early phase clinical trials, and innovative therapeutic strategies in acute myeloid leukemia (AML) with a particular interest in the development of novel targeted therapeutic approaches such as menin inhibitors, immunotherapeutic approaches, and therapies targeted towards differentiation and apoptotic pathways. He has designed and developed multiple Phase I-II studies in AML and oversees a robust clinical research program in Leukemia at University of North Carolina.